BCLI Stock UPDATES Brainstorm Cell Ther (BCLI) 0.2850 09/13/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Brainstorm Cell Ther (BCLI) 0.2850 $BCLI

BrainStorm Provides Update on NASDAQ Uplisting Process
Marketwire - Tue Sep 09, 5:29AM CDT
Brainstorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that on September 15, 2014, it plans to effect a 1 for 15 reverse split of its issued and outstanding common stock as part of its intended plan to pursue a stock listing on the NASDAQ Capital Market.

BrainStorm to Present at the Rodman and Renshaw 16th Annual Global Investment Conference
ACCESSWIRE - Thu Sep 04, 8:21AM CDT
NEW YORK, NY and PETACH TIKVAH, ISRAEL / ACCESSWIRE / September 4, 2014 / BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate overview of BrainStorm and NurOwn(TM), its proprietary stem cell platform currently in a phase 2 trial in Amyotrophic Lateral Sclerosis. Details of the presentation are as follows:

BrainStorm Granted European Patent Covering its Stem Cells for the Treatment of CNS Diseases
ACCESSWIRE - Wed Sep 03, 7:46AM CDT
NEW YORK, NY and PETACH TIKVAH, Israel / ACCESSWIRE / September 3, 2014 / BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the European Patent Office (EPO) has granted the company patent number EP1893747, entitled "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases." The European Patent Application will be published in the European Patent Bulletin 14/36 on September 3, 2014. This patent covers a method of production of the company's proprietary NurOwn™ technology, which consists of mesenchymal stem cells induced to secrete large quantities of neurotrophic factors, for use in the treatment of neurodegenerative diseases.

FDA Clears Mayo Clinic for Manufacture of NurOwn and Participation in BrainStorm's Phase 2 ALS Trial
ACCESSWIRE - Mon Aug 18, 7:13AM CDT
NEW YORK, NY and PETACH TIKVAH, Israel /ACCESSWIRE / August 18, 2014 / BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Mayo Clinic Human Cellular Therapy Laboratory in Rochester, Minn. for production of NurOwn™, BrainStorm's proprietary autologous mesenchymal stem cells secreting neurotrophic factors (MSC-NTF). BrainStorm will continue working with the Mayo clinical team to complete the necessary steps to allow the site to begin enrolling subjects into its ongoing phase 2 study of NurOwn™, which is designed to evaluate the safety and efficacy of the transplantation of or NurOwn™ in patients with Amyotrophic Lateral Sclerosis (ALS).

BrainStorm Receives Notice of Allowance on US Patent
ACCESSWIRE - Mon Jul 28, 8:47AM CDT
NEW YORK, NY and PETACH TIKVAH, Israel / ACCESSWIRE / July 28, 2014 / BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, received Notice of Allowance from the United States Patent Office for Patent Application 12/994,761, titled "Mesenchymal Stem Cells for the Treatment of CNS Diseases."

BrainStorm Announces that University of Massachusetts Memorial Medical Center to Begin Enrolling Patients in Phase 2 ALS Clinical Trial
eTeligis - Tue Jul 15, 10:04AM CDT
Petach Tikvah, Israel, New York, NY, United States, via eTeligis Inc., 07/15/2014 - - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the University of Massachusetts (UMass) Memorial Medical Center in Worcester, MA will begin enrolling patients into the Company's randomized, double-bling placebo-controlled phase 2 clinical trial in Amyotrophic Lateral Sclerosis (ALS). UMass Memorial is the second site to become active of the three sites participating in this trial. The other two clinical sites participating in the multi-center trial are Massachusetts General Hospital (MGH), which began enrolling patients into the trial last month, and the Mayo Clinic, which is expected to become active in the third quarter of 2014. The Dana Farber Cancer Institute's Connell and O'Reilly Cell Manipulation Core Facility will manufacture NurOwn cells for MGH and UMass Memorial.

BrainStorm publishes study of preclinical multidose in mice of NurOwn
M2 - Fri Jul 11, 7:01AM CDT
Adult stem cell company BrainStorm Cell Therapeutics (OTCQB:BCLI) announced on Friday that it has published a preclinical study about the safety of single and repeated intramuscular administration of NurOwn, its proprietary mesenchymal stem cells that are induced to secrete a variety of neurotrophic factors, in the Clinical and Translational Medicine journal.

BrainStorm Announces Publication of Preclinical Multidose Study of NurOwn
Marketwire - Fri Jul 11, 6:08AM CDT
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today publication of an important preclinical study in the journal Clinical and Translational Medicine. This paper describes the safety of single and repeated intramuscular administration of NurOwn, the Company's proprietary mesenchymal stem cells that are induced to secrete a variety of neurotrophic factors. NurOwn is in clinical development for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and has demonstrated efficacy in preclinical models of a variety of neurodegenerative diseases, including Parkinson's disease, Huntingon's disease and multiple sclerosis. The results published today are important because they establish that repeated doses of NurOwn are safe in mice and more specifically, that mice generate only minimal immune response after repeated exposure to NurOwn, which are human cells. These data will help support the use of multiple doses of NurOwn in future clinical trials.

OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell Therapeutics, Inc., Advanced Cell Technology, Inc.
PR Newswire Europe - Tue Jul 01, 7:01AM CDT
LONDON, July 1, 2014 /PRNewswire/ --

BrainStorm and Octane Successfully Construct a Bioreactor Prototype for Industrial-Scale Manufacturing or NurOwn Stem Cells
Marketwire - Fri Jun 27, 8:50AM CDT
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, and Octane Biotech Inc., a Canadian firm that focuses on clinical systems for cell and tissue therapy, announced today that they have reached an important milestone in their technology collaboration, successfully constructing an Alpha prototype of a customized bioreactor for BrainStorm's NurOwn(TM) neurotrophic-factor secreting mesenchymal stem cells. The proprietary bioreactor under development will provide BrainStorm with large-scale manufacturing capabilities, enabling it to achieve economies of scale for its autologous stem cell product.

BrainStorm Cell Therapeutics Raises $10.5 Million in Private Placement Financing
Marketwire - Fri Jun 13, 8:30AM CDT
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System therapeutics, today announced that it has entered into definitive agreements with a group of investors, including several healthcare-focused funds, in connection with a private placement of common stock and warrants to purchase common stock. Upon the closing of this financing, BrainStorm will receive gross proceeds of $10.5 million, resulting from the issuance and sale of 42.0 million shares of common stock at a price per share of $0.25, a 15% discount to the 30 day volume-weighted average price of $0.294. The purchasers will also receive warrants to purchase up to 42.0 million shares of common stock at an exercise price of $0.348 per share. The warrants are exercisable immediately upon closing of the private placement and have a term of three years.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Scientific Games Takes Big Buck Hunter to Lotteries

Updated Category News Views 84

A mounted arcade cabinet is an odd place to find lottery growth, yet Scientific Games may be onto something with its exclusive Big Buck Hunter licensing deal. Announced November 19, 2026, the arrangement lets the company carry a 26-year-old arcade franchise into U.S. and Canadian instant scratch games, Fast Play, draw games, digital products and second-chance promotions....

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 57

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 157

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading
Eight O'Clock Adds Blonde Roast Pods to Its Lineup

Updated Category News Views 166

A lighter cup of coffee just became Eight O'Clock Coffee's newest swing at the single-serve shelf. On Nov. 19, 2026, the company said it introduced Blonde Roast K-Cup pods, a bright and smooth option aimed at drinkers who prefer a lighter roast. The product is available through Keurig.com and Amazon. That is the whole announcement, and frankly it is better to keep it that...

Continue Reading
CMA Wins Spotlight Greenberg Traurig’s Music Bench

Updated Category News Views 119

Four trophies on one awards night can say plenty about the machinery behind a music career, even if nobody should confuse a CMA acceptance speech with a balance-sheet event. Greenberg Traurig’s entertainment practice is celebrating client wins at the 60th annual CMA Awards, held Nov. 18, 2026: three honors tied to Miranda Lambert and one for Brooks & Dunn. For investors...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 56

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer

Updated Category News Views 144

Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...

Continue Reading
Clickstop's Urbana Expansion Bets on Durable Demand

Updated Category News Views 81

A patch of turned Iowa dirt can say plenty about a company’s nerve. Clickstop broke ground in Urbana on Nov. 19, 2026, for a 43,000-square-foot building, and the message is pretty plain: management believes its recent growth has legs. For a privately held, employee-owned operator serving trucking, construction, lifting and rigging, that is not a casual decision....

Continue Reading
Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 47

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
HLRBO's Data-Heavy Rebuild Changes Hunting Lease Market

Updated Category News Views 149

A hunting lease used to begin with hearsay, blurry photos, and a whole lot of hoping. HLRBO is trying to drag that stubbornly analog process into a data-rich, phone-first marketplace, and frankly, it is about time. The company rebuilt its web and mobile platforms around parcel information, plain-language AI search, mobile lease completion, and its Land IQ™ scoring...

Continue Reading

Top 5 Most Recently Viewed Articles

Denvix Welcomes NBA Star Jimmy Butler III as Brand Ambassador

Updated Category News Views 244

Denvix Welcomes NBA Superstar Jimmy Butler III Denvix, an innovative consumer electronics company, has proudly announced that NBA superstar Jimmy Butler III will serve as its newest Global Brand Ambassador. This collaboration marks a significant milestone in both Denvix's marketing strategy and Butler's brand partnerships, as he takes on a vital role representing Denvix...

Continue Reading
Cleanspark's Options Trading Insights and Market Position

Updated Category News Views 193

Understanding Cleanspark's Options Trading Dynamics A notable shift in sentiment has emerged among large investors towards Cleanspark, a significant player in the bitcoin mining sector. Investors' Action in the Options Market Upon analyzing the recent options trading activity related to Cleanspark (CLSK), we found that a total of 11 trades were executed. Notably, 45% of...

Continue Reading
PU Prime Strengthens Global Presence with AFA Partnership

Updated Category News Views 201

PU Prime and AFA's Strategic Partnership Unveiled in Madrid In a significant development highlighting the global commitment to football and innovation, PU Prime and the Argentina Football Association (AFA) proudly formalized their partnership during a vibrant signing ceremony at the Argentina Football Academy Vallecas in Madrid. The event marked a crucial step in...

Continue Reading
Exciting Partnership Between Parma City Schools and Varsity Tutors

Updated Category News Views 121

Parma City Schools Partners with Varsity Tutors Parma City Schools recently unveiled an intriguing collaboration with Varsity Tutors for Schools, part of the Nerdy family, a renowned leader in live online tutoring. This partnership aims to furnish students across the district with valuable academic support through the innovative Varsity Tutors platform. About the...

Continue Reading
HopSkipDrive Launches Innovative School Transport in Kansas City

Updated Category News Views 242

HopSkipDrive Expands Its Reach to Kansas City HopSkipDrive, a pioneering technology company, is set to launch its services in Kansas City. This initiative aims to provide local schools with access to an expansive network of highly vetted caregivers known as CareDrivers. The goal is to supplement traditional school transportation methods, including yellow school buses,...

Continue Reading